U.S. markets closed
  • S&P 500

    4,124.66
    -16.93 (-0.41%)
     
  • Dow 30

    33,730.89
    +53.62 (+0.16%)
     
  • Nasdaq

    13,857.84
    -138.26 (-0.99%)
     
  • Russell 2000

    2,247.72
    +18.79 (+0.84%)
     
  • Crude Oil

    62.75
    +2.57 (+4.27%)
     
  • Gold

    1,736.50
    -11.10 (-0.64%)
     
  • Silver

    25.48
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1990
    +0.0036 (+0.30%)
     
  • 10-Yr Bond

    1.6380
    +0.0150 (+0.92%)
     
  • GBP/USD

    1.3776
    +0.0024 (+0.17%)
     
  • USD/JPY

    108.9080
    -0.1400 (-0.13%)
     
  • BTC-USD

    62,769.67
    -413.20 (-0.65%)
     
  • CMC Crypto 200

    1,360.41
    -15.36 (-1.12%)
     
  • FTSE 100

    6,939.58
    +49.09 (+0.71%)
     
  • Nikkei 225

    29,620.99
    -130.61 (-0.44%)
     

Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005019/en/

Contacts

Vertex Pharmaceuticals Incorporated Investors:
Michael Partridge, 617-341-6108
Zach Barber, 617-341-6470
Brenda Eustace, 617-341-6187
Manisha Pai, 617-429-6891